If 2017 ended right now, it would be the worst year for Merck & Co. (NYSE: MRK) stock since the financial crisis of 2008. There are still several weeks remaining before the year ends, of course, but the big pharma stock is down at a time when most of its peers are performing quite well.
While some declines in stock valuations reflect long-term problems, others are only temporary. Which is the case for Merck? Here are arguments for and against buying the stock right now -- and which argument is stronger.
Image source: Getty Images.
Source: Fool.com